Melanotan II (MT-2): Research, Mechanism, and What the Evidence Actually Shows

What Is Melanotan II?

Melanotan II (MT-2) is a synthetic peptide hormone that activates melanocortin receptors in the body. It was originally developed as a potential sunless tanning agent but has broad biological effects including skin darkening, increased sexual arousal, appetite suppression, and nausea.

MT-2 was developed in the 1980s at the University of Arizona by researchers studying melanocortin peptides. The original goal was to create a compound that could stimulate the body’s natural tanning response without UV exposure. This was motivated by skin cancer prevention — if people could tan without sun exposure, the thinking went, they might reduce their UV-related cancer risk.

The peptide is a cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring hormone that regulates skin pigmentation, appetite, and sexual function. “Cyclic” means the molecule is folded into a ring shape, which makes it more resistant to breakdown in the body and more potent than the linear natural hormone.

However, MT-2 turned out to be far less selective than researchers hoped. Rather than activating only the pigmentation pathway, it activates multiple melanocortin receptors throughout the body. This broad activity is why a single peptide can cause tanning, sexual arousal, appetite suppression, and nausea simultaneously.

MT-2 has never been approved by any regulatory agency for any indication. It is not an approved drug, supplement, or cosmetic ingredient. Despite this, it has been widely used in unregulated contexts for tanning and sexual enhancement, making it one of the most commonly self-administered research peptides worldwide.

Who this page is for, and who it isn’t for

This page is for researchers, clinicians, and individuals who want a clear, evidence-weighted understanding of what Melanotan II does and what is known — and unknown — about its effects. It is not a usage guide, a tanning protocol, or a product recommendation. MT-2 is not approved for human use. Anyone considering peptides for any purpose should consult a qualified healthcare provider.

How Melanotan II Works

MT-2 produces its wide range of effects by activating multiple melanocortin receptors. Understanding which receptors it hits — and where those receptors are located in the body — explains why a “tanning peptide” also affects sex drive, appetite, and the gut.

The Melanocortin Receptor System

The body has five melanocortin receptors, labeled MC1R through MC5R. Each one controls different biological functions. MT-2 activates several of them with varying potency. This lack of selectivity is the source of both its effects and its side effects.

MC1R — Skin pigmentation. MC1R is found on melanocytes, the pigment-producing cells in the skin. When MT-2 activates MC1R, melanocytes produce more melanin. This is the same process that occurs naturally during tanning, but MT-2 triggers it without requiring UV exposure. The result is skin darkening.

Why this matters: MC1R activation is the intended effect of MT-2. It is the reason the peptide was developed. Naturally fair-skinned individuals have MC1R variants that produce less melanin; MT-2 can partially override this by strongly stimulating whatever MC1R activity is available.

MC4R — Sexual arousal and appetite. MC4R is found in the brain, particularly in the hypothalamus — the brain region that governs sexual behavior, hunger, and energy balance. When MT-2 activates MC4R, two things happen: sexual desire increases and appetite decreases. This is not a secondary or minor effect. MC4R activation is why MT-2 users frequently report strong, sometimes unexpected sexual arousal alongside reduced hunger.

The sexual arousal effects of MT-2 were actually the basis for developing PT-141 (bremelanotide), which was derived from MT-2 specifically to isolate the sexual function effects through more selective MC4R activation.

MC3R — Energy balance and inflammation. MC3R is found in the brain and peripheral tissues. It plays a role in energy homeostasis and inflammatory regulation. MT-2 activates MC3R, which may contribute to some of its metabolic and appetite effects.

MC5R — Exocrine function. MC5R is involved in sebaceous gland secretion and other exocrine functions. Its role in MT-2’s effects is not well characterized.

Why One Peptide Causes So Many Different Effects

The key concept is off-target effects. MT-2 was designed to activate MC1R for tanning. But because the melanocortin receptors share structural similarities, MT-2 also activates MC3R, MC4R, and MC5R.

This is why a person using MT-2 for tanning may simultaneously experience sexual arousal, reduced appetite, nausea, and facial flushing. These are not side effects in the traditional sense — they are direct pharmacological effects of the peptide acting on receptors throughout the body. The peptide cannot distinguish between “I want the tanning effect” and “I don’t want the sexual arousal effect.” It activates all accessible melanocortin receptors.

A receptor agonist like MT-2 cannot be selective about which tissues it reaches. Once injected, it circulates throughout the body and activates melanocortin receptors wherever it finds them.

Pharmacokinetics

The pharmacokinetics of MT-2 have been studied in limited clinical settings. The peptide is administered by subcutaneous injection because it would be broken down in the digestive tract if taken orally. After injection, it is absorbed into the bloodstream and distributed throughout the body.

MT-2’s cyclic structure gives it greater metabolic stability than linear α-MSH. This means it persists in the body longer and produces more sustained receptor activation. The tanning effects accumulate over multiple administrations, while the acute effects (nausea, flushing, arousal) typically occur within hours of each injection.

What the Research Shows

MT-2 has been studied in several small clinical trials and numerous preclinical experiments. The evidence base is limited compared to FDA-approved peptides, but it is not nonexistent. The research consistently shows that MT-2 works for skin darkening and has real physiological effects on sexual function and appetite, but the safety profile — particularly for long-term use — is poorly characterized.

Human Evidence

Tanning and pigmentation studies. Multiple small clinical trials have demonstrated that MT-2 increases skin pigmentation in humans. In a study by Dorr et al. (1996), subcutaneous MT-2 administration produced significant tanning in fair-skinned subjects without UV exposure. The effect was dose-dependent and measurable by reflectance spectrometry (Dorr et al., 1996).

A subsequent study confirmed the tanning effect and showed that MT-2 combined with UV exposure produced greater pigmentation than UV alone (Barnetson et al., 2006). These studies enrolled small numbers of participants (typically 10–30), but the tanning effect was consistent and objectively measured.

Sexual function observations. During early tanning trials, male subjects reported spontaneous erections as an unintended effect. This observation was significant enough to redirect an entire line of pharmaceutical research, ultimately leading to the development of PT-141 (bremelanotide) as a dedicated sexual function compound.

Formal assessment of MT-2’s sexual effects in humans is limited. Most data comes from incidental observations during tanning studies or from user self-reports. The sexual effects are attributed to MC4R activation in the brain, and this mechanism has been validated through the PT-141 clinical program.

Appetite effects. Reduced appetite has been reported by participants in clinical studies and is consistent with the known role of MC4R in appetite regulation. However, MT-2 has not been formally studied as a weight management agent in humans.

Animal Evidence

Animal studies have provided more detailed mechanistic data:

• Pigmentation: MT-2 produces skin darkening in multiple animal models, consistent with MC1R activation.
• Sexual behavior: In rodent and primate models, MT-2 increases sexual motivation and copulatory behavior, supporting the MC4R mechanism (Wessells et al., 2003).
• Appetite suppression: MC4R agonism by MT-2 reduces food intake in rodent models. This is consistent with the broader understanding that the melanocortin system is a key regulator of energy balance.
• Erectile function: In animal models of erectile dysfunction, MT-2 improved erectile response, further supporting central nervous system-mediated sexual effects.

What the Research Does Not Show

It is equally important to note what has not been established:

• MT-2 has not been shown to provide meaningful UV protection despite increasing pigmentation. Melanin type and distribution matter, and MT-2-induced tanning may not provide the same photoprotection as natural tanning.
• Long-term safety has not been evaluated in any controlled setting.
• The cancer risk implications of stimulating melanocyte activity are unresolved.
• Optimal dosing has not been established through dose-finding clinical trials.

Known Adverse Effects

MT-2’s side effect profile is characterized by frequent acute effects and uncertain long-term risks. Because the peptide has never undergone full clinical development, the adverse effect data comes from small studies, case reports, and community self-reporting.

Common Acute Effects

• Nausea. The most frequently reported side effect. Nausea can be significant, particularly during initial use or at higher doses. It appears to be mediated by melanocortin receptor activation in the brainstem and gut. Many users report that nausea diminishes with repeated use.

• Facial flushing. Warmth and redness of the face, typically occurring within minutes to hours of injection. This is a vascular effect likely related to melanocortin signaling.

• Appetite suppression. Reduced hunger is a direct MC4R effect. Some users consider this a benefit; others find it disruptive. The magnitude varies between individuals.

• Sexual arousal. Spontaneous or heightened sexual arousal, including erections in men. This is a direct pharmacological effect of MC4R activation, not a side effect in the pharmacological sense — it is a predictable receptor-mediated response.

• Injection site reactions. Localized redness, swelling, or discomfort at the injection site.

• Fatigue and yawning. Reported by some users, particularly after injection. The mechanism is not well characterized.

Dermatological Concerns

• Mole darkening and new nevi. MT-2 stimulates melanocytes indiscriminately. This includes melanocytes in existing moles. Multiple case reports document darkening of existing moles and the appearance of new nevi during MT-2 use. Changes in moles are a clinical red flag for melanoma, which creates a diagnostic challenge: is a changing mole a benign response to MT-2, or an early melanoma?

• Atypical mole changes. Some case reports describe dysplastic (atypical) nevi emerging during MT-2 use. Whether MT-2 can promote melanocyte dysplasia or merely reveal pre-existing tendencies is unknown.

• Melanoma risk — the central unanswered question. MT-2 stimulates melanocyte proliferation and melanin production. Melanoma is a cancer of melanocytes. The theoretical concern is that chronic melanocyte stimulation could promote malignant transformation, accelerate the growth of pre-existing melanomas, or obscure early melanoma detection by making mole changes harder to interpret. This concern has not been confirmed by epidemiological data, but it has also not been ruled out by long-term studies. Several published case reports describe melanoma diagnoses in MT-2 users, though establishing causation from case reports is not possible.

Cardiovascular Effects

• Blood pressure changes. Transient increases in blood pressure have been observed in clinical studies. This is consistent with melanocortin-mediated cardiovascular effects.

Long-Term Risks: Genuinely Unknown

The honest assessment is that long-term risks of MT-2 are not characterized. No controlled study has followed MT-2 users over years. The theoretical concerns — melanoma risk, effects of chronic melanocyte stimulation, potential immunological effects, and cardiovascular implications — remain theoretical precisely because the long-term studies that could resolve them have not been conducted.

This uncertainty is not the same as safety. “We don’t know if it’s dangerous long-term” is a fundamentally different statement from “it’s safe long-term.” For a deeper discussion of this distinction, see our peptide safety guide.

Regulatory Status

MT-2 has a clear regulatory status: it is not approved anywhere for any use.

FDA (United States)

The FDA has not approved Melanotan II for any indication. The FDA has issued warnings about MT-2 products, citing safety concerns and the absence of regulatory review. MT-2 is not approved as a drug, a supplement, or a cosmetic ingredient in the United States.

EMA (European Union)

The European Medicines Agency has not approved MT-2. Several European national regulators have issued warnings about unlicensed MT-2 products.

TGA (Australia)

The Australian Therapeutic Goods Administration has issued multiple warnings about MT-2, describing it as an unregistered product with unproven safety and efficacy.

WADA (World Anti-Doping Agency)

MT-2 is prohibited under the WADA Prohibited List. It falls under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes who test positive for MT-2 or its metabolites face doping violations.

The Regulatory Gap

MT-2 exists in a regulatory gray area common to many research peptides. It is sold as a “research chemical” or “not for human consumption” through online vendors. Despite these disclaimers, it is widely used for tanning and sexual enhancement. The lack of approval means there are no manufacturing standards, no quality requirements, and no post-marketing surveillance for adverse effects.

Key Unknowns and Open Questions

Several important questions about MT-2 remain genuinely unanswered. These are not edge cases — they are central to evaluating the peptide’s risk-benefit profile.

Does MT-2 increase melanoma risk? The most important unanswered question. MT-2 stimulates the very cell type that becomes cancerous in melanoma. Case reports exist but cannot establish causation. No epidemiological study has examined this question. Until it is answered, the risk remains theoretically plausible and empirically unresolved.

Does MT-2-induced tanning provide UV protection? The original rationale for MT-2 was skin cancer prevention through sunless tanning. Whether the melanin produced by MT-2 provides meaningful photoprotection has not been conclusively established. Melanin type (eumelanin vs. pheomelanin), distribution, and concentration all affect UV protection, and MT-2 may not replicate natural tanning in these respects.

What are the effects of chronic melanocyte stimulation? Regular MT-2 use means ongoing stimulation of melanocytes over months or years. The consequences of this chronic stimulation on melanocyte biology, DNA damage repair, and tumor surveillance are unknown.

Are the dermatological changes (mole darkening, new nevi) reversible? Some users report mole changes that persist after stopping MT-2. Whether these represent permanent changes to melanocyte populations or temporary effects that resolve over longer time periods is not well documented.

What is the interaction with UV exposure? Many MT-2 users combine the peptide with UV exposure (tanning beds or sunlight) to enhance the tanning effect. Whether MT-2 plus UV creates synergistic risks beyond those of either alone is unstudied.

How does MT-2 affect individuals with melanoma risk factors? People with fair skin, many moles, family history of melanoma, or atypical mole syndrome may face different risk profiles. No data exists specifically for these populations.

Summary and Takeaways

Melanotan II is a broad-acting melanocortin agonist that reliably produces skin darkening in humans. It also produces sexual arousal, appetite suppression, and nausea as direct pharmacological effects of its non-selective receptor activation.

What is reasonably well established:

• MT-2 causes skin darkening through MC1R activation. This effect is real and measurable.
• MT-2 causes sexual arousal through MC4R activation. This effect was significant enough to spawn a separate FDA-approved drug (PT-141/bremelanotide).
• Nausea, flushing, and appetite suppression are common acute effects.
• Mole darkening and new nevi formation occur in some users.

What is genuinely uncertain:

• Whether MT-2 increases melanoma risk. This is the most consequential unknown.
• Whether the tanning effect provides meaningful UV protection.
• What happens with chronic, long-term melanocyte stimulation.
• The full long-term safety profile for any organ system.

What is clear:

• MT-2 is not approved by any regulatory agency for any use.
• It has not undergone the safety evaluation required for drug approval.
• The available evidence is insufficient to make confident statements about long-term safety.
• Anyone considering MT-2 should understand that they are accepting unknown risks, not well-characterized ones.

MT-2 is a peptide where the biological effects are real but the safety picture is incomplete. The gap between “it works” and “it is safe” has not been bridged by adequate research.

Frequently Asked Questions

Is Melanotan II the same as PT-141?

No. PT-141 (bremelanotide) was derived from Melanotan II but was modified to be more selective for sexual function effects through MC4R. PT-141 has undergone full FDA clinical development and is approved as Vyleesi for hypoactive sexual desire disorder. MT-2 is the broader, non-selective parent compound that has never been approved for any use. PT-141 produces less tanning and more targeted sexual function effects than MT-2.

Can MT-2 cause melanoma?

This has not been proven or disproven. MT-2 stimulates melanocytes, the cell type involved in melanoma. Case reports describe melanoma in MT-2 users, but case reports cannot establish causation. The theoretical concern is plausible, and the absence of long-term safety data means the question remains open. Anyone with melanoma risk factors should be particularly cautious.

Does MT-2 provide protection against UV damage?

This is uncertain. While MT-2 increases melanin production, whether the resulting pigmentation provides meaningful protection against UV-induced DNA damage has not been conclusively demonstrated. Melanin type, distribution, and concentration all affect UV protection. MT-2-induced tanning should not be considered equivalent to sunscreen or other proven UV protection methods.

Why is MT-2 still widely used if it’s not approved?

MT-2 produces a cosmetically desirable effect (tanning) without UV exposure, which appeals to a large market. It is inexpensive relative to other tanning methods, easy to source from online research chemical vendors, and its acute effects are obvious and reinforcing. The regulatory gap — sold as “not for human consumption” but widely used by humans — is common to many research peptides.

Can the nausea be avoided?

Some users report that lower doses, gradual dose titration, and timing around meals reduce nausea severity. Nausea often diminishes with repeated use. However, nausea is a direct pharmacological effect of melanocortin receptor activation, not an impurity or sensitivity issue. It cannot be completely eliminated in all users at effective doses.

How is MT-2 different from Melanotan I?

Melanotan I (afamelanotide) is a more selective MC1R agonist. It produces tanning with fewer off-target effects (less sexual arousal, less nausea). Afamelanotide has actually been approved in some markets (Scenesse, approved by the EMA for erythropoietic protoporphyria). MT-2 is the less selective compound with broader receptor activity.

References

1. Dorr RT, et al. “Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.” Arch Dermatol. 2004;140(7):827-35. PubMed
2. Dorr RT, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci. 1996;58(20):1777-84. PubMed
3. Barnetson RS, et al. “[Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers.” J Invest Dermatol. 2006;126(8):1869-78. PubMed
4. Wessells H, et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” Int J Impot Res. 2003;15 Suppl 5:S72-5. PubMed
5. Pfaus JG, et al. “A review of animal and human data on the melanocortin system and sexual function.” Eur J Pharmacol. 2013;704(1-3):270-9. PubMed
6. Brennan R, et al. “Melanotan II as a lifestyle drug — an overview.” Perform Enhanc Health. 2014;3(2):78-85.
7. Reid C, Fitzgerald T. “Adverse effects associated with the use of Melanotan.” Ir Med J. 2013;106(5):148-9.
8. Langan EA, et al. “Darkening of pre-existing melanocytic naevi and development of new naevi with the use of Melanotan-II.” Br J Dermatol. 2009;161(3):707-8.

Related Articles

Peptide

AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

An evidence-first look at AOD-9604 — the GH fragment studied for fat loss. Clinical trial results, mechanism of action, safety data, and an honest assessment of efficacy.

Peptide

Kisspeptin-10: Research, Mechanism, and Evidence for Reproductive Hormone Regulation

An evidence-based review of Kisspeptin-10 — the neuropeptide that regulates the HPG axis. Clinical research on LH, testosterone, fertility applications, and practical limitations.

Peptide

PT-141 (Bremelanotide): Research, Mechanism, and Clinical Evidence for Sexual Function

An evidence-based review of PT-141 (bremelanotide/Vyleesi) — the FDA-approved melanocortin receptor agonist studied for sexual desire. Clinical trial data, mechanism, and side effects.